Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911688 · ClinicalTrials.gov registry record · Phase 2
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
A Phase 2 study of Allergic Asthma, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02911688: Completed Phase 2 study of Allergic Asthma, sponsored by University of North Carolina, Chapel Hill.
NCT02911688 is a Phase 2 study of Allergic Asthma that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 18 participants, below the 201-participant average among 4 other Allergic Asthma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02911688, a Phase 2 study of Allergic Asthma, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To study the effects of 1200mg gamma tocopherol, a form of vitamin E, given daily on the response of the airway in mild asthmatics after exposure to ozone (O3)
Primary Outcome
Participants provide induced sputum samples before and 6 hours after Ozone exposure for measurements of inflammatory cells. The analysis will determine if gamma tocopherol pre-treatment reduces ozone-induced sputum percent neutrophils compared to placebo pre-treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG gamma tocopherol
Study Locations (1)
North Carolina
- Center for Environmental Medicine, Asthma and Lung Biology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 2 |
What the finished NCT02911688 record still lists
NCT02911688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 201-participant average among 4 other Allergic Asthma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Allergic Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02911688 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02911688 about?
NCT02911688 is a clinical study titled "Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure". To study the effects of 1200mg gamma tocopherol, a form of vitamin E, given daily on the response of the airway in mild asthmatics after exposure to ozone (O3)
What is the current status of trial NCT02911688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-09. Estimated completion is 2019-02-13.
What conditions does trial NCT02911688 study?
This clinical trial studies the following conditions: Allergic Asthma.
What interventions are being tested in trial NCT02911688?
The interventions under investigation include: Placebo (DRUG), gamma tocopherol (DRUG).
Who is sponsoring clinical trial NCT02911688?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02911688 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of the Role of Histamine in Children With Asthma
COMPLETED · Phase 2
-
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
RECRUITING · Phase 3
-
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
COMPLETED
-
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia